Navigation Links
New Class of Drugs Might Treat Many Conditions

Vaptans ease painful periods, glaucoma, depression and many other diseases, researchers say

FRIDAY, May 9 (HealthDay News) -- A new class of drugs called vaptans may be able to treat a wide variety of conditions including painful periods, brain hemorrhage, psychotic disorders and glaucoma, Belgian researchers report.

Vaptans, short for vasopressin-receptor antagonists, work by targeting the vasopressin hormone system, which plays an important role in controlling blood and water volume in the body. These drugs, which can be taken orally or intravenously, block the action of vasopressin, according to the report in the May 10 issue of The Lancet.

In the report, Dr. Guy Decaux, from Erasmus University Hospital in Brussels, and his colleagues reviewed the current state of vaptans, of which there are several subclasses, that have been development or are under development.

Among these new drugs are relcovaptan, which has shown initial positive results in treating painful periods, as well as Raynaud's disease, which affects blood flow to the arms and legs, and tocolysis, (premature labor, leading to premature birth).

Another subclass of vaptans that include mozavaptan, lixivaptan, satavaptan and tolvaptan are diuretics, which remove water from the body, while maintaining the body's electrolyte, or salt mineral, balance. Other diuretics don't maintain the body's electrolyte balance, the researchers noted.

Some vaptans can be used to treat hyponatremia, which is a life-threatening loss of salt. Currently, conivaptan is the only vaptan approved by the U.S. Food and Drug Administration for treating hyponatremia.

Other vaptans in development might be used to treat kidney failure, diabetic nephropathy, a progressive kidney disease associated with diabetes, cirrhosis and depression, the researchers wrote.

In addition, early studies of vaptans for treating glaucoma, Menire's disease-- an inner ear condition affecting hearing and balance -- brain hemorrhage, and small-cell lung cancer, have had promising results, Decaux's team noted.

Despite these promising results, one expert isn't ready to called vaptans a miracle cure yet.

"This is nice review of an emerging class of drugs," said Dr. Gary S. Francis, director of the coronary intensive care unit at the Cleveland Clinic. "But it is a little early to know if they will prove to be highly useful."

More information

For more on conivaptan, visit the U.S. Food and Drug Administration.

SOURCES: Gary S. Francis, M.D., director, coronary intensive care unit, Cleveland Clinic; May 10, 2008, The Lancet

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
2. ADDA Kicks Off AD/HD Awareness Campaign with Four Regional Conferences Beginning Sept. 29 and Series of Fall Teleclasses
3. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
4. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
5. Theater Classes Help Docs Bedside Manners
6. Tarpinian: Misclassification is Theft
7. New class of RNA molecules may be important in human cancer
8. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
9. Consumer Group: Hillary Clintons Mandatory Health Insurance Purchase Plan is an Act of War on the Middle Class Family That Cant Afford $12k Policy
10. SATELLITE BROADCAST: Consumer Group Says Hillary Clintons Mandatory Health Insurance Plan is an Act of War on the Middle Class that Cant Afford $12k Policy
11. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
Post Your Comments:
Related Image:
New Class of Drugs Might Treat Many Conditions
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology: